Hypertriglyceridemia affects 30% of the population in the US. Very high level of
triglycerides is a known risk factor for pancreatitis. In addition, studies have shown that
hypertriglyceridemia is an independent risk factor for cardiovascular disease.
Diazoxide is a KATP channel opener. It has been approved by the FDA as an oral suspension for
the treatment of hyperinsulinemic hypoglycemic conditions and as an IV solution for malignant
hypertension. Preclinical and clinical studies suggest that diazoxide can be a potential
therapeutic agent for hypertriglyceridemia.
Diazoxide choline is a novel, highly crystalline proprietary salt of diazoxide, which has
been formulated as a controlled-release tablet suitable for once per day dosing. This current
study is designed to assess the effect of diazoxide choline on triglycerides in subjects with
baseline hypertriglyceridemia. In addition, the effects on other lipid parameters, glucose
and insulin, body weight as well as the safety and tolerability of diazoxide choline will be
assessed.